Share This Author
Myocardial reperfusion injury.
This review focuses on the mechanisms of the injury, on attempts to protect the heart against it, and on promising new approaches to cardioprotection during percutaneous coronary intervention.
Myocardial ischemia-reperfusion injury: a neglected therapeutic target.
A number of new therapeutic strategies currently under investigation for preventing myocardial reperfusion injury have the potential to improve clinical outcomes in patients with acute MI treated with PPCI.
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.
Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
- S. Ong, S. Subrayan, Shiang Y. Lim, D. Yellon, S. Davidson, D. Hausenloy
- 11 May 2010
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury, suggesting a novel pharmacological strategy for cardioprotection.
Postconditioning: A Form of “Modified Reperfusion” Protects the Myocardium by Activating the Phosphatidylinositol 3-Kinase–Akt Pathway
It is shown for the first time that ischemic Postcond protects the myocardium by activating the prosurvival kinases PI3K–Akt, eNOS, and p70S6K in accordance with the RISK pathway.
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.
- D. Hausenloy, A. Tsang, M. Mocanu, D. Yellon
- Biology, MedicineAmerican journal of physiology. Heart and…
- 1 February 2005
The reperfusion phase following sustained ischemia plays an essential role in mediating IPC-induced protection and it is demonstrated that IPC protects the heart by phosphorylating the prosurvival kinases Akt and ERK-1/2 at reperfusions.
Survival kinases in ischemic preconditioning and postconditioning.
Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance.
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection
The administration of pharmacological agents which are known to activate the RISK pathway, when applied as adjuvant therapy to current myocardial reperfusion strategies for patients presenting with an AMI, should lead to improved clinical outcomes in this patient group.